Viewing Study NCT06090318

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:37 AM
Ignite Modification Date: 2026-06-05 @ 1:29 PM
Study NCT ID: NCT06090318
Status: WITHDRAWN
Last Update Posted: 2023-10-19
First Post: 2022-11-14
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Sponsor: Rain Oncology Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Tumor View
None CDKN2A View
None NSCLC View
None Urothelial Carcinoma Bladder View
None Melanoma View
None Pancreas Adenocarcinoma View
None HNSCC View
None Renal Cell Carcinoma View
None Mesothelioma View
None Gastric Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CDKN2A View
None WT TP53 View
None Advanced Solid Tumor View
None Wild-type P53 View